Cyclotron Radiochemistry and Chemistry

$203,215P50FY2012CANIH

Sloan-Kettering Inst Can Research, New York NY

Investigators

Linked publications & trials

Paper 36608299 Paper 34667111 Paper 33441295 Paper 33052220 Paper 32971780 Paper 32826318 Paper 32169913 Paper 31891487 Paper 31601700 Paper 30480549 Paper 30026636 Paper 29691406 Paper 29388903 Paper 29029482 Paper 28990809 Paper 28345023 Paper 28202506 Paper 28108545 Paper 27903863 Paper 27740967 Paper 27706135 Paper 27694056 Paper 27693541 Paper 27669459 Paper 27485481 Paper 27454297 Paper 27393689 Paper 27347557 Paper 27182557 Paper 27158135 Paper 26806023 Paper 26687859 Paper 26596724 Paper 26516195 Paper 26503962 Paper 26377636 Paper 26318038 Paper 26291010 Paper 26273541 Paper 26261257 Paper 26194713 Paper 26155428 Paper 26141216 Paper 26025962 Paper 25998714 Paper 25941595 Paper 25871623 Paper 25840974 Paper 25836013 Paper 25812157 Paper 25751502 Paper 25721207 Paper 25673762 Paper 25629637 Paper 25624432 Paper 25608772 Paper 25577038 Paper 25527015 Paper 25444931 Paper 25385459 Paper 25355699 Paper 25204552 Paper 25202987 Paper 25202339 Paper 25186392 Paper 25143071 Paper 24989696 Paper 24944121 Paper 24666719 Paper 24604591 Paper 24573553 Paper 24475817 Paper 24445347 Paper 24219178 Paper 24173571 Paper 24002508 Paper 23833310 Paper 23722591 Paper 23318292 Paper 23308046 Paper 23224977 Paper 23153539 Paper 22914772 Paper 22819195 Paper 22777834 Paper 22727887 Paper 22617062 Paper 22576209 Paper 22418029 Paper 22363636 Paper 22343591 Paper 22306323 Paper 22231045 Paper 22140653 Paper 21994185 Paper 21984797 Paper 21856782 Paper 21844011 Paper 21764785 Paper 21670497

Abstract

Specialized Resource A - Cyclotron Radiochemistry and Chemistry (SR-A). lCMlC-3 is reliant on the production and supply of existing and novel radiopharmaceuticals and radiochemicals. In this Specialized Resource we will continue to generate a tool box of radiolabeled drugs based around 18F-tracers as well as drugs based on the longer-lived nuclides 64Cu, 86Y, 89Zr and 1241. This will allow us to augment the existing lCMIC-3 projects, the ICMIC Developmental Projects, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients. The Specific Aims of this Specialized Resource are as follows: (A) to undertake specialized radiochemistry and labeling chemistry in support of the ICMIC projects and developmental projects; (B) To function as an evolving resource - to provide (and design) new compounds as required as the ICMIC research matures; and, (C) to act as a central resource for the translation of new drugs to the clinical setting.

View original record on NIH RePORTER →